Some of the blood specimens collected in the United States for the NIH’s All of Us research program starting on January 2, 2020, have antibodies against SARS-CoV-2.
Engineered viruses that don’t replicate provide a tractable model for scientists to safely study SARS-CoV-2, including research into vaccine efficacy and emerging variants.
Researchers identify deletions in the N-terminal domain of the spike protein that allow the coronavirus to avoid antibody neutralization and that may contribute to the emergence of new variants.
SARS-CoV-2 antibodies detected in blood donor samples indicate infections could have occurred in the US more than a month before the first confirmed case, but some experts remain skeptical.
Fewer than 1 in 10 dialysis patients sampled had antibodies against the novel coronavirus as of July, indicating that the greater population is far from levels required to achieve herd immunity.
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?